Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)

NCT01164267 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone B-cell Lymphoma

Interventions

DRUG: Everolimus

Sponsor

International Extranodal Lymphoma Study Group (IELSG)